Speakers - Sachs Associates
Speakers - Sachs Associates
Speakers - Sachs Associates
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
CONTACT<br />
Martin Bonde, PhD, BComm<br />
Chief Executive Officer<br />
ADDRESS<br />
Ole Maaloesvej 3<br />
2200 Koebenhavn N<br />
Denmark<br />
TELEPHONE<br />
+45 2025 3560<br />
EMAIL<br />
mb@epitherapeutics.dk<br />
YEAR FOUNDED<br />
2008<br />
EpiTherapeutics ApS<br />
www.epitherapeutics.dk<br />
FINANCIAL SUMMARY<br />
Raised $ 12.2 mill from 5 investors • Novo Seeds • Seed Capital • Lundbeckfond Ventures • Astellas Venture<br />
• Merck Serono Venture.<br />
COMPANY PROFILE<br />
EpiTherapeutics is developing novel innovative cancer drugs based on the world leading research in epigenetics<br />
conducted by Professor Kristian Helin and his group at Biotech Research & Innovation Centre (BRIC) at University<br />
of Copenhagen.<br />
EpiTherapeutics’ development programs are focused on enzymes involved in the regulation of transcription in<br />
cancer – current programs target histone demethylases and methyltransferases. Subsequent developments may<br />
identify other potential clinical indications outside oncology.<br />
In December 2010, EpiTherapeutics signed a drug discovery collaboration with Abbott Laboratories.<br />
EpiTherapeutics employs 25 FTE and is headquartered in Copenhagen.<br />
MANAGEMENT<br />
Martin Bonde, PhD, BComm, Chief Executive Officer<br />
t back :: next u<br />
WELCOME PHARMA LICENSING GROUPS<br />
SPEAKERS<br />
PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />
ORGANISERS
Change language